Q3 2024 Earnings Summary
- Uncertainty in Achieving 16.5% Operating Margin in 2025: Baxter's executives indicated that bridging from current operating margins to the targeted 16.5% operating margin in 2025 is "really complicated," raising concerns about the company's ability to meet this goal.
- Impact of Stranded Costs on Operating Margins: The company is experiencing significant headwinds from stranded costs related to the pending sale of its Kidney Care business. These stranded costs negatively impacted operating margin by approximately 250 basis points in the quarter, leading to a decline in adjusted operating margins by 90 to 100 basis points for the full year 2024 on a continuing operations basis.
- Significant Disruption from Hurricane Helene: Baxter's largest manufacturing facility, North Cove, suffered unprecedented devastation from Hurricane Helene. This disruption is expected to negatively impact fourth-quarter sales by approximately $200 million, including an estimated $150 million to $160 million impact on Medical Products & Therapies (MPT) sales. Full production recovery is not expected until the end of the year, posing risks to operational continuity and financial performance.
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Revenue Growth (core, ex. Kidney Care) | FY 2024 | 4% to 5% | no current guidance | no current guidance |
Total Sales Growth | FY 2024 | no prior guidance | 1% to 2% as reported (≈2% cc), incl. ~100 bps hurricane impact | no prior guidance |
MPT Sales Growth | FY 2024 | no prior guidance | 2% to 3% (constant currency) | no prior guidance |
HST Sales Growth | FY 2024 | no prior guidance | decline low single digits | no prior guidance |
Pharma Sales Growth | FY 2024 | no prior guidance | ≈10% | no prior guidance |
Kidney Care Sales Growth | FY 2024 | no prior guidance | ≈2% | no prior guidance |
Adjusted Operating Margin | FY 2024 | no prior guidance | increase by >50 bps (includes ~50 bps hurricane headwind) | no prior guidance |
Adjusted Operating Margin (continuing ops) | FY 2024 | no prior guidance | decline 90–100 bps (includes 250 bps stranded-cost headwind) | no prior guidance |
Adjusted EPS (total company) | FY 2024 | no prior guidance | $2.90 – $2.94 (includes $0.15 – $0.20 hurricane headwind) | no prior guidance |
Adjusted EPS (continuing ops) | FY 2024 | no prior guidance | $1.81 – $1.84 (includes $0.42 stranded-cost headwind) | no prior guidance |
Tax Rate (total company) | FY 2024 | no prior guidance | ≈22% | no prior guidance |
Tax Rate (continuing ops) | FY 2024 | no prior guidance | ≈18.5% | no prior guidance |
Diluted Share Count | FY 2024 | no prior guidance | ≈511 million shares | no prior guidance |
Sales (total & continuing ops) | Q4 2024 | no prior guidance | decline low single digits (reported & cc), incl. ~500 bps hurricane impact | no prior guidance |
Adjusted EPS (total company) | Q4 2024 | no prior guidance | $0.77 – $0.81 (includes $0.15 – $0.20 hurricane headwind, $0.08 depreciation benefit) | no prior guidance |
Adjusted EPS (continuing ops) | Q4 2024 | no prior guidance | $0.50 – $0.53 (includes $0.12 stranded-cost headwind) | no prior guidance |
| Metric | Period | Guidance | Actual | Performance |
|---|---|---|---|---|
Revenue Growth | Q3 2024 | Expects to exit the year at the higher end of 4% to 5% growth | Actual total revenue declined from 3,572In Q3 2023 to 479In Q3 2024 (≈ -86.6% YoY) | Missed |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Novum IQ infusion pump platform | Key growth driver in Q2 and Q1 with high customer interest and early U.S. sales. | Continues strong momentum; infusion hardware up 50% driven by this platform. | Sustained momentum |
Medical Products & Therapies (MPT) | Consistently grew 4–6% in prior quarters with broad portfolio strength. | Grew 7%, led by strong Novum IQ adoption and advanced surgery demand. | Continued solid performance |
Operating margin expansion | No explicit 14.5%–16.5% range in earlier calls; margins gradually improving. | At ~14.5% in Q3, impacted by stranded costs; plan to reach 16.5% by 2025. | Explicit path to higher margin |
Hurricane Helene impact | Not previously mentioned in Q2, Q1, or Q4 2023. | New disruption at North Cove facility; ~$200M Q4 revenue impact. | New factor with near-term negative effect |
TSA income | Not discussed in earlier periods (Q2, Q1, Q4 2023). | Short-term offset to stranded costs; will help in 2025. | New mention |
4% to 5% organic growth target | Consistent message in Q2 and Q1 with confidence in sustaining 4%–5% growth. | Reaffirmed for 2025, driven by product launches and market restocking. | Key recurring metric |
Non-kidney businesses momentum | Highlighted momentum in Q2 and Q1, excluding kidney care softness. | Solid growth in MPT, HST, and Pharma segments. | Continued positivity |
Stranded costs | Acknowledged in Q2 as a key focus post-kidney separation. | 240 bps margin impact in Q3, to be offset by TSA income and cost measures by 2027. | Detailed elimination plan |
Double-digit EPS growth | Previously guided for double-digit EPS growth in Q4 2023 call. | Adjusted EPS from continuing ops up 14% in Q3; total company EPS up 18%. | Ongoing robust earnings improvement |
-
2025 Guidance and Hurricane Impact
Q: Confidence in meeting 2025 guidance despite hurricane and HST issues?
A: Management reaffirms confidence in achieving 4%-5% revenue growth and 16.5% operating margin in 2025 despite minimal first-quarter impact from Hurricane Helene. They cite normalization of the HST business, significant growth in pumps (up 50% in 2024, continuing into 2025), positive pricing impacts, operational efficiencies, and cost-containment efforts as key drivers. -
Margin Target and Stranded Costs
Q: Is the 16.5% margin target achievable or exceedable? How will you offset stranded costs and lost TSA income?
A: Management views the 16.5% operating margin as an anchoring point for post-separation growth, expecting continued margin expansion over time. They plan to eliminate stranded costs by 2027 through actions like rationalizing distribution centers and rightsizing the organization. TSA income in 2025 will offset some expenses, and proactive cost-containment measures are underway. -
IV Fluid Revenue Recovery
Q: Will the $150 million IV fluid revenue loss recover in 2025?
A: While there's potential upside from restocking the market after the IV fluid shortage, management hasn't factored it into guidance yet. They expect destocking effects to balance out in 2025 and see opportunities not yet explored. -
Operating Margin Bridge and Dividend Policy
Q: How do you reconcile current margins with 16.5% target? Will you maintain the dividend?
A: Current margins include stranded costs not yet offset by TSA income or cost measures. The 16.5% target reflects expected cost containment and TSA offsets in 2025. Management plans to reset the dividend based on the company's new size but is committed to maintaining a dividend. -
Revenue Acceleration Drivers
Q: What drives revenue growth acceleration to 4%-5% next year?
A: Drivers include normalization of the HST business, significant growth in pumps (hardware up 50% in 2024), new product launches, and resolution of operational issues. Front Line Care is expected to return to normal growth, and strong performance in pumps and sets will continue. -
Capital Allocation and Spending Trajectory
Q: How are you balancing investments with cost measures?
A: Management continues to invest in R&D for innovation while expecting expense leverage in SG&A through cost-containment measures. They anticipate gaining leverage from growth and are carefully managing expenses to offset impacts like the IV fluid shortage. -
China Impact and Tariffs
Q: What is the impact of China performance and potential tariffs?
A: Post-separation, China will represent less than 2% of sales. Baxter is less exposed to China-related risks, including VBPs and tariffs, and does not expect significant impact. -
Novum Pump Uptake
Q: How is the Novum pump uptake progressing?
A: The Novum pump launch is going extremely well, with market share gains of 2% to 2.5% expected by year-end. Infusion hardware sales are up 50% in 2024, with strong growth expected to continue into 2025. -
IV Solutions Manufacturing and Pricing
Q: Will you spread out manufacturing to reduce risk? Will IV bag pricing increase?
A: Baxter utilizes a global network of plants to mitigate risk, with facilities in countries like Spain, Canada, and China. They've invested over $0.5 billion in their facility since 2016 and recovered quickly from disruptions. While acknowledging the critical nature of IV solutions, they did not comment on pricing.